For liraglutide (Figures 3S and 4S), substantially increased incidence risks of pancreatitis, acute nephritis, thyroid cancer, thyroid dysfunction, and leukemia were observed in comparison to both insulin and metformin groups. This evidence concerns the gene INS and thyroid gland carcinoma.